April 21st, 2026

The call conveyed a broadly positive outlook: solid quarterly growth (sales +4%, organic +5%), strong bookings ($9.8B) and a large backlog ($96B), improving margins, significant program accelerations (B-21 production +25%, Sentinel milestones), and active investments to expand capacity. Near-term negatives include a weak Space quarter driven by one-time timing and program adjustments (NGI and GEM 63XL), Q1 cash use and sizable multi-year CapEx for B-21, and execution/timing risks tied to supplier scaling and program testing. On balance, the positive operational and backlog momentum, reaffirmed guidance, and material strategic wins and investments outweigh the manageable near-term challenges.

Company Guidance

The company reaffirmed 2026 guidance with full-year sales of $43.5–$44.0 billion and segment operating income targeted at a low-to-mid 11% margin, expecting sales to accelerate through the year (Q2 high single‑digit sequential sales growth) and cash flow to ramp with the largest generation in Q4; full‑year capex was raised to $1.85 billion (including an incremental $200 million for B‑21) while free cash flow guidance was maintained at $3.1–$3.5 billion. Management noted a Q1 operating backdrop of $9.9 billion sales (up 4% YoY, organic +5%), $9.8 billion of awards, $96 billion backlog, segment operating income above $1 billion (10.8% margins), diluted EPS of $6.14, approx. $1.8 billion use of cash in Q1 and over $2 billion cash on hand, and emphasized program-level expectations such as Sentinel representing ~6–7% of revenue (low double‑digit growth in 2026 toward ~10% over time), B‑21 nearing ~10% of revenue with a 25% production rate increase and ~ $2.5 billion company‑funded investment phased over multiple years, and weapons/missile‑defense businesses each at about 10% of company sales and positioned to grow faster than the company average.